Research and Markets (http://www.researchandmarkets.com/research/a15751/china_blood_produc) has announced the addition of the "China Blood Products Industry Report, 2009" report to their offering.
The blood products industry has a strong ability to withstand risks and immunity to global financial crisis since it is not greatly influenced by periodicity. Owing to large demand gap, strict supervision, high entry barrier and slower supply growth etc in blood products industry, the prices of China's blood products has soared up and corporate profitability also has increased significantly.
China's blood products industry has been in the transition of policy adjustment since 2003. The plasma collection registered approximately 3,100 tons in 2008 due to restrictions from raw materials and the changes in industry policy.
The report makes an in-depth analysis of the status quo of China's blood product industry, points out the gap between Chinese blood products companies and overseas peers, predicts the development trends, and discusses the investment opportunities and risks. In addition, it also focuses on the research of current operation and development trend of China's seven key blood product companies, such as Hualan Biological Engineering Inc.